



Dedicated To Life

July 21, 2022

BSE Limited

1st Floor,
P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Zyduslife

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated July 21, 2022 titled "**Zydus receives final approval from the USFDA for Norepinephrine Bitartrate Injection**".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,

For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Zydus receives final approval from the USFDA for Norepinephrine Bitartrate Injection

Ahmedabad, India, 21 July, 2022

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited), has received final approval from the United States Food and Drug Administration (USFDA) to market Norepinephrine Bitartrate Injection USP, 4 mg/4 mL (1 mg/mL) Single-Dose Vial. (USRLD: Levophed).

Norepinephrine Bitartrate is indicated for restoration of blood pressure in adult patients with acute hypotensive state. The drug will be manufactured at the group's topical injectable manufacturing facility at Jarod, India.

Norepinephrine Bitartrate Injection USP, 1mg/1 mL had annual sales of US\$ 63.8 million in the United States according to IQVIA data (IQVIA MAT May 2022).

The group now has 317 approvals and has so far filed over 420* ANDAs since the commencement of the filing process in FY 2003-04.

*(*as of 31st March 2022)*



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878